Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2129)

[Fuchs24]

Was gibts hier für News, dass der Kurs so steigt?

[77mike77]

Novavax to Participate in Upcoming Conferences

https://finance.yahoo.com/news/novavax-participate-upcoming-…

[77mike77]

es tut sich was bei NVAX aktuell 12% plus in 🇺🇸

[Magnetfeldfredy]

Interessaner Bericht, Novavax könnte die Lösung haben, ich bin sehr gespannt auf die finalen Ergebnisse:

Vaccines Fight Covid, But Can They Stop the Spread?
Sam Fazeli
Thu, November 19, 2020, 4:00 PM GMT+1

(Bloomberg Opinion) -- Covid-19 vaccines, now closer to becoming widely available than ever, are the ultimate tool to help tame the virus and allow people to return to some semblance of pre-pandemic life. Despite the recent good news on their progress, though, it’s unclear whether they can truly deliver on the promise of a return to normal. Why? Because as much as some vaccines have proved effective in protecting against Covid-19 symptoms, they haven’t yet shown that they can stop the virus from spreading. In fact, some vaccine makers haven’t even tested for that. And that’s a problem.

Shots in development by Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE have shown stunning early success at reducing illness in infected patients. Just this week, Pfizer revealed that its vaccine was 94% effective in test subjects over 65 years old – the demographic group that needs the vaccine most. There’s still a lot left to learn, not least how protective these inoculations may be in the long run. But so far, there’s reason to believe that vaccines will induce the kind of immunity that Covid-19 survivors have developed. As for possible virus mutations, the latest vaccine technologies appear able to cope with them for now.

What’s still unknown, however, is whether the vaccines also prevent transmission of the virus. Might vaccinated people who never develop Covid-19 symptoms still carry the virus and pass it to others? This is an important question, especially if many people refuse to be inoculated. Many public opinion surveys have found that a significant proportion of people are skeptical of vaccines, or at least have some misgivings. But if a vaccine does not meaningfully reduce viral transmission, it leaves the unimmunized relatively vulnerable. And if the coronavirus continues to be passed from person to person, it has a better chance to keep mutating and potentially evade our defenses.

Is it possible to make sure a vaccine can block transmission? That’s a difficult thing to do completely because it requires that the shot stop the virus from replicating, even in the open spaces of the nose and throat where it’s tough for vaccines to exert their effects. It is possible, though. Logic suggests that a vaccine capable of triggering a very strong immune response would also provide so-called sterilizing immunity - that is, block transmission. Among the many vaccines now in development, Novavax Inc.’s has been found to have induced the highest antibody levels, even after taking into account the differences in the way antibodies are measured.

Preclinical studies have also shown that some of the vaccines in development achieved complete viral suppression in monkeys. Johnson & Johnson, Novavax and Pfizer-BioNTech were all able to virtually eradicate the virus from animal respiratory tracts. (Vaccines in development by AstraZeneca Plc and Moderna didn’t quite manage this.) But these are not human trials, of course.

Unfortunately, it’s not yet possible to find out whether vaccines are able to produce a sterilizing immunity based on current clinical trials as they have not been set up to provide that information. If participants had been asked for weekly nasal swabs, scientists could compare viral loads in vaccinated subjects and unvaccinated ones who developed Covid-19. But the Pfizer-BioNTech and Moderna trials required nasal swabs only on vaccination days and then again if subjects reported symptoms.

At this point, the only way to find out whether vaccines confer sterilizing immunity is by doing another trial. Given the stakes involved, this might be warranted. Meanwhile, companies that are about to start a late-stage trial, such as Novavax, have the time and opportunity to include weekly swab tests in their protocols. It’s something they should consider.

Meanwhile, where does that leave us? It’s clear we’ll all be better off with vaccines than without them, but if the virus can still spread and possibly mutate, then we can’t let our guard down even when shots are distributed. Absent widespread adoption of the vaccine, our best defense remains mask-wearing and other mitigation efforts, as well as rigorous testing and tracing regimes to better identify and stifle outbreaks.

The vaccine news has been much better than anyone dared to imagine, but without knowing even more about what the vaccine can do, the hard work is still ahead of us in the war against Covid-19.

This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.

Sam Fazeli is senior pharmaceuticals analyst for Bloomberg Intelligence and director of research for EMEA.

For more articles like this, please visit us at bloomberg.com/opinion

Subscribe now to stay ahead with the most trusted business news source.

©2020 Bloomberg L.P.

[Magnetfeldfredy]

Sterile Immunität bei den Affen, wenn das bei den Menschen klappt sind wir "best in class":

Novavax vaccine stops coronavirus spreading between monkeys – raising hopes of a jab that will eliminate virus as well as stopping people falling ill

Novavax said vaccine 'prevented infection' between rhesus macaque monkeys
Scientists last night described the breakthrough as 'exciting' but urged caution
They warned of differences between way viruses work in monkeys and humans

By Alex Lawson Senior City Correspondent For The Mail On Sunday

Published: 00:27 GMT, 22 November 2020 | Updated: 00:34 GMT, 22 November 2020

e-mail

779
shares

99

View comments

A company in the global race to produce a Covid-19 vaccine has raised hopes that its jab could stop humans spreading the virus to each other following successful trials in monkeys.

Novavax told The Mail on Sunday that its vaccine 'prevented infection' between rhesus macaque monkeys in testing.

The US pharmaceuticals firm is now going to study whether the vaccine could have the same effect in the human population – potentially helping to bring the pandemic to an end.
Novavax told The Mail on Sunday that its vaccine 'prevented infection' between rhesus macaque monkeys in testing (file photo)
+2

Novavax told The Mail on Sunday that its vaccine 'prevented infection' between rhesus macaque monkeys in testing (file photo)

'If it happens in humans, that would be the dream scenario for a vaccine,' said Dr Gregory Glenn, president of research and development at Novavax.

Scientists last night described the breakthrough as 'exciting' but urged caution, warning of significant differences between the way viruses work in trials on monkeys and in human populations.

The race to produce the earliest and most effective vaccine is reaching fever pitch, with a major announcement on trials by Britain's AstraZeneca and Oxford University expected within days.

The promising results so far from US giants Pfizer and Moderna show their jabs should protect people from falling ill – but there is insufficient data on whether they stop the spread of Covid to others.
RELATED ARTICLES

Previous
1
Next

Tale of Two Cities: Crowds of Christmas shoppers flock to...
Boris to kill off the 10pm curfew: Lockdown WILL end on...

Share this article
Share

If asymptomatic people who have received a vaccine are still able to infect others, the virus could keep spreading.

After a successful trial on mice, Novavax gave a dozen rhesus macaque monkeys two doses of its vaccine of varying strengths three weeks apart before infecting them with Covid.

The virus did not make most of the animals sick as it did not appear in their noses.

It only replicated in the lungs of one monkey, which received the lowest dose of the vaccine. That monkey fought off the infection in four days.

Dr Glenn said the antibodies created by the vaccine had been 'so strong', they had created 'sterile immunity' – preventing the virus moving from the monkey's lungs to its nose and stopping the animals spreading Covid.
The US pharmaceuticals firm is now going to study whether the vaccine could have the same effect in the human population (file photo)
+2

The US pharmaceuticals firm is now going to study whether the vaccine could have the same effect in the human population (file photo)

Monkeys are commonly used in US vaccine and drug studies and typically represent the last step before human clinical trials.

Unlike humans, they experience only mild symptoms of Covid-19.

The Novavax vaccine is being trialled in humans across the UK.

The company initially began testing 9,000 people – including broadcaster Adrian Chiles, who has written about finding the experience 'weirdly fulfilling' – and is expanding the late-stage trial to 15,000 people.

Initial results are expected early next year or potentially sooner. Danny Altmann, a professor of immunology at Imperial College London, said the data on Novavax's trial was keenly awaited by scientists.

He added: 'Human life is much more variable than a macaque monkey study in a lab, because we're all being infected with different doses all the time, whether you're standing in the supermarket queue or the pub.

'You don't know how it's going to play out in real life, but it's pretty exciting.'

Maryland-based Novavax, which has received funding from Microsoft founder Bill Gates' foundation and the US Government, was founded in 1987 and is relatively small compared to its vaccine rivals. It has never before brought a vaccine to market.

If a vaccine could create sterile immunity it would likely make it the most sought-after of the more than 200 Covid jabs that are currently being developed.

The UK has committed to 60 million doses of the Novavax vaccine, which will be produced at Fujifilm Diosynth Biotechnologies in County Durham.
Share or comment on this article: Novavax vaccine stops coronavirus spreading between monkeys

[mfierke]

Antwort auf Beitrag Nr.: 65.702.994 von nicolani am 13.11.20 19:22:04

ich danke dir für diese Zeilen, dann weiß ich was ich tun muss

[nicolani]

bin jetzt für immer massiv short!

[Scontovaluta]

"...The Novavax vaccine candidate works in a similar way to the UQ version, in that both use a slightly different technique to generate a protein that looks like the protein on the surface of SARS-CoV-2, causing an immune response in humans…"

Dieses Prinzip ist leider relativ anfällig. Veränderte mutierte Oberflächenproteinvarianten des ausgewählten Zielproteins am mutierten Virus werden nicht erkannt.

[GLASKUGELMANN]

bin gespannt wie es hier weitergeht...….mein Kursziel bleibt 4$ für Novavax….bis zur nächsten Pandemie...…

es bleibt spannend.

[Magnetfeldfredy]

Das hört sich super an, best in class:

Experts hail addition of two more vaccines to Australia's virus 'portfolio'
For our free coronavirus pandemic coverage, learn more here.
Stuart Layt
By Stuart Layt
November 5, 2020 — 10.00pm

Leave a comment

The expert in charge of two separate Australian clinical trials of coronavirus vaccine candidates says the latest vaccine agreement announced by the federal government is vital in helping the country eventually reopen fully next year.

Prime Minister Scott Morrison confirmed on Thursday that Australia would spend $1.5 billion to add the Novavax and the Pfizer vaccines to the country’s eventual pool of available vaccines.
Prime Minister Scott Morrison has announced Australia has secured a combined 50 million doses of two COVID-19 vaccine candidates.

Prime Minister Scott Morrison has announced Australia has secured a combined 50 million doses of two COVID-19 vaccine candidates.Credit:Brook Mitchell/Getty Images

Australia now has agreements for four separate vaccine candidates, including the two announced on Thursday along with the University of Queensland vaccine and the University of Oxford/AstraZeneca candidate.

Paul Griffin, a clinical disease specialist and the local lead clinical trial investigator for Nucleus Network, which is running the Phase 1 and 2 studies of the Novavax vaccine as well as for the UQ/ CSL candidate, said the deal announced by the federal government did not detract from the deals already announced.

Rather, Dr Griffin said, it boosted Australia’s “vaccine portfolio”.

“This gives us additional options and given they’re slightly different technologies they’re very complimentary to the two vaccines we already have an agreement for,” he said.
The vaccine candidates secured by Australia

Newly announced:

Novavax- 40 million doses - currently in stage 2 and 3 clinical trials
Pfizer- 10 million doses - currently in stage 2 and 3 clinical trials

Previously announced:

UQ/CSL - 51 million doses - currently in an expanded stage 1 clinical trial
University of Oxford/ AstraZeneca - 33.8 million doses - currently in stage 2 and 3 clinical trials

“Having an arrangement now for four vaccines gives us a better chance of having a vaccine that’s likely to be as effective as possible and hopefully next year.”

The Novavax vaccine candidate works in a similar way to the UQ version, in that both use a slightly different technique to generate a protein that looks like the protein on the surface of SARS-CoV-2, causing an immune response in humans.

The Pfizer vaccine meanwhile uses “messenger RNA” (mRNA) - molecules that, when injected, cause the body’s own cells to generate the viral protein, which then generates the immune response.

The University of Oxford/AstraZeneca candidate uses a different way again, using a harmless viral “shell” containing the genetic code for the COVID-19 virus spike protein, which it then produces in the body and generates the immune response.
Australian microbiologist Dr Paul Griffin is running trials of two of the vaccines in Australia's "portfolio" of candidates.

Australian microbiologist Dr Paul Griffin is running trials of two of the vaccines in Australia's "portfolio" of candidates.Credit:Justin McManus

People will likely need two doses each of the Novavax vaccine which is why there has been 40 million doses ordered by the Commonwealth compared to 10 million of the Pfizer candidate.

Dr Griffin said the clinical trials for both the vaccines he was working with were progressing well, with the Novavax candidate likely to be ready as early as April, while other candidates will become ready later in 2021.

“Certainly with all the results that we have so far it looks like [the Novavax candidate] may be one that is safe and effective,” he said.
Related Article
UQ's vaccine candidate started human trials in July. They are now expanding the trial to include 96 more people over 55 years old.
Coronavirus pandemic
Older people wanted for expanded UQ COVID-19 vaccine trial

“The big thing to remember with the availability of a vaccine is that it’s clearly the critical step we need, but the day one of these vaccines is approved for use it’s not going to be like flicking a switch and returning to normal.

“It will be a huge step in the right direction but we’re still going to need some basic infection control and mitigation running in parallel while we deal with the complex rollout to get these vaccines to everybody.”

University of New South Wales infectious diseases expert Raina MacIntyre said she would like to see Australia add even more vaccines to its portfolio.

“In my view, we should diversify further,” Professor MacIntyre said.

“In the case of a vaccine against a new disease, until vaccines are rolled out in the post-licensure phase, we won’t know which ones are the safest and most efficacious."

Kylie Quinn from RMIT University agreed, and said the Novavax vaccine could give protection to a particularly vulnerable group.

“A similar vaccine for influenza is being tested by Novavax in a Phase III clinical trial specifically in older individuals,” Dr Quinn said.

“The trial is still ongoing but initial results showed that the Novavax vaccine generated larger immune responses in older people as compared to the standard flu vaccine.

“The key thing here is that Australia is positioning itself to have more vaccines in its tool-kit.”